Mario Scrima

Dr. Mario Scrima


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2008 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
SCSonia Cantel
Sonia Cantel
AIAlexandra Le Chevalier Isaad
Alexandra Le Chevalier Isaad
MSMario Scrima
Mario Scrima
JLJay J. Levy
Jay J. Levy
RDRichard D. DiMarchi
Richard D. DiMarchi
MCMichael Chorev
Michael Chorev

11 January 2010 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
MSMario Scrima
Mario Scrima
ACAlexandra Le Chevalier‐Isaad
Alexandra Le Chevalier‐Isaad
PRPaolo Rovero
Paolo Rovero
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini
MCMichael Chorev
Michael Chorev
Anna Maria D’UrsiAnna Maria D’Ursi
Anna Maria D’Ursi

20 October 2010 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
SPSang Ho Park
Sang Ho Park
BDBibhuti B. Das
Bibhuti B. Das
AAAnna A. De Angelis
Anna A. De Angelis
MSMario Scrima
Mario Scrima
SOStanley Opella
Stanley Opella

15 April 2015 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
ACAmedeo Capobianco
Amedeo Capobianco
Tonino CarusoTonino Caruso
Tonino Caruso
ADAnna Maria D’uRsi
Anna Maria D’uRsi
SFSandra Fusco
Sandra Fusco
Annalisa MasiAnnalisa Masi
Annalisa Masi
Andrea PelusoAndrea Peluso
Andrea Peluso

13 November 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CTChiara Testa
Chiara Testa
MSMario Scrima
Mario Scrima
Manuela GrimaldiManuela Grimaldi
Manuela Grimaldi
ADAnna M. D’uRsi
Anna M. D’uRsi
MDMarvin L. Dirain
Marvin L. Dirain
Anna Maria PapiniAnna Maria Papini
Anna Maria Papini
Side chain-to-side chain cyclizations represent a strategy to select a family of bioactive conformations by reducing the entropy and enhancing the stabilization of functional ligand-induced receptor conformations. This structural manipulation contributes to increased target specificity, enhanced biological potency, improved pharmacokinetic properties, increased functional potency, and lowered metabolic susceptibility. The CuI-catalyzed azide–alkyne 1,3-dipolar Huisgen’s cycloaddition, the prototypic click reaction, presents a promising opportunity to develop a new paradigm for an orthogonal bioorganic and intramolecular side chain-to-side chain cyclization. In fact, the proteolytic stable 1,4- or 4,1-disubstituted [1,2,3]triazolyl moiety is isosteric with the peptide bond and can function as a surrogate of the classical side chain-to-side chain lactam forming bridge. Herein we report the design, synthesis, conformational analysis, and functional biological activity of a series of i-to-i+5 1,4- and 4,1-disubstituted [1,2,3]triazole-bridged cyclopeptides derived from MT-II, the homodetic Asp5 to Lys10 side chain-to-side chain bridged heptapeptide, an extensively studied agonist of melanocortin receptors.

12 July 2016 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Manuela GrimaldiManuela Grimaldi
Manuela Grimaldi
SMSara Di Marino
Sara Di Marino
FFFulvio Florenzano
Fulvio Florenzano
MCMaria Teresa Ciotta
Maria Teresa Ciotta
SNStefania Lucia Nori
Stefania Lucia Nori
MSMario Scrima
Mario Scrima
Background: For long time Alzheimer's disease has been attributed to a cholinergic deficit. More recently, it has been considered dependent on the accumulation of the amyloid beta peptide (Aβ), which promotes neuronal loss and impairs neuronal function. Results/methodology: In the present study, using biophysical and biochemical experiments we tested the hypothesis that in addition to its role as a neurotransmitter, acetylcholine may exert its action as an anti-Alzheimer agent through a direct interaction with Aβ. Conclusion: Our data provide evidence that acetylcholine favors the soluble peptide conformation and exerts a neuroprotective effect against the neuroinflammatory and toxic effects of Aβ. The present paper paves the way toward the development of new polyfunctional anti-Alzheimer therapeutics capable of intervening on both the cholinergic transmission and the Aβ aggregation. Graphical Abstract